Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
Annette Hasenburg Prof., Dr, med
Annette Hasenburg Prof., Dr, med Advisory Board
Oliver Sartor MD
Oliver Sartor MD Advisory Board
See All Experts
story of the week
Published in Oncology and
1 other channel

Journal Scan / Research · July 13, 2017

Molecular Tools to Identify Ultra–Low Risk Patients With Indolent Breast Cancers

JAMA Oncology

 

 Save  Recommend
 Share

Additional Info

JAMA Oncology
Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades
JAMA Oncol 2017 Jun 29;[EPub Ahead of Print], LJ Esserman, C Yau, CK Thompson, LJ van 't Veer, AD Borowsky, KA Hoadley, NP Tobin, B Nordenskjöld, T Fornander, O Stål, CC Benz, LS Lindström

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Recently Updated